BiotechTube
GRIN Therapeutics

GRIN Therapeutics

Cambridge, United States· Est.
grintherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $146M

Overview

GRIN Therapeutics, founded in 2020 and based in Cambridge, USA, is a private, pre-revenue biotech focused on developing small molecule therapeutics for severe pediatric neurodevelopmental disorders. The company's lead asset is radiprodil, an investigational therapy targeting dysregulated NMDA receptor activity, which is currently in a global Phase 3 trial for GRIN-NDD and being explored for other conditions like tuberous sclerosis complex. GRIN Therapeutics represents a precision medicine approach to a high-need, rare disease space with significant scientific and clinical validation potential.

Neurodevelopmental DisordersPediatric EpilepsyRare Neurological Diseases

Technology Platform

Precision medicine approach targeting dysregulated NMDA receptor activity, specifically using selective negative allosteric modulators of the GluN2B subunit for disorders with gain-of-function variants.

Funding History

2
Total raised:$146M
Venture$140M
Seed$6M

Opportunities

The primary opportunity lies in addressing a complete unmet need in severe, rare pediatric disorders, enabling potential for orphan drug pricing and expedited regulatory pathways.
Successful proof-of-concept in GRIN-NDD could unlock larger markets in more prevalent conditions like Tuberous Sclerosis Complex, where treatment-resistant epilepsy is a major challenge.

Risk Factors

The key risk is clinical failure of the lead asset radiprodil in its ongoing Phase 3 trial.
Additional risks include the challenges of measuring efficacy in neurodevelopmental disorders, regulatory hurdles for pediatric rare diseases, and the complexities of commercializing a therapy for an ultra-rare, geographically dispersed patient population.

Competitive Landscape

The competitive landscape for GRIN-NDD is sparse due to its rarity, but GRIN Therapeutics faces indirect competition from other companies developing NMDA receptor modulators for broader neurological indications. In secondary targets like TSC, it would compete with other anti-seizure medications and disease-modifying agents in development. The company's precision genetic targeting is a key differentiator.

More companies in Small Molecule Drugs →More companies in United States →